Friday , January 22 2021

Florencia González Lizárraga investigates Parkinson's and received a prize



Proud of her work, her team and the level of science done in Tucumán, Florencia González Lizárraga He is grateful for the difference he has received from the Argentine society for biophysics, the institution of its most important type in the country. He was awarded the Jorge Ponce Hornos Prize after being selected among 350 scientists from all over the country. "This work is my PhD dissertation (she must be a doctor in biological sciences). I'm the first author of the work, but we discuss these issues as a team," she explains.

The study of Florence was conducted in the Department of Applied Molecular and Cellular Medicine (Immca), which is dependent on the UNT, Conicet and Ministry of Health in the province and is responsible for Rosana Chehín. The work is also considered by the UBA's Advanced Microscopy Center as a leader Lia Pietrasanta. There was yesterday Florence when he spoke on the phone with LA GACETA.

The basis for the research of young researchers is an antibiotic called dioxycycline, which belongs to the group of tetracyclines. This antibiotic has the ability to interact with the Alpha-synuclein protein, which is responsible for the dopasinergic neuron's death (those communicating with other neurons through dopamine). These are the neurons that die in those people who suffer from Parkinson's.

But doxycycline is not suitable for long-term diseases such as neurodegenerative diseases because it can generate resistance to bacteria.

"The other part of the work is to have found a drug called COL 3, which is also tetracycline but genetically modified so it has no antibiotic activity so it will not generate resistance. It has anti-inflammatory effect and makes the protein alpha- synuclein is not toxic. Consequently, there is no death of dopano neurons.

"In this way, Parkinson's disease stops. That is, it's not a palliative treatment like the current treatments," emphasizes Florencia.

Of course, research is still in a laboratory phase. In vitro and in vivo tests are performed, but there is still a long way to go to a stage of clinical trials in humans. Nevertheless, it is undoubtedly a big hope.

The other mention of the Ponce Hornos Prize was also for a Tucuman: Luciana Medina, for a work on Alzheimer's disease.


Source link